Bromantane Clinical Use (Russia)

What It Is

Bromantane is a small-molecule adamantane derivative (N-(2-adamantyl)-N-(para-bromophenyl)amine) developed at the Zakusov State Research Institute of Pharmacology of the Russian Academy of Medical Sciences beginning in the 1980s. It belongs to a pharmacological category rarely discussed in Western medicine — the actoprotectors — compounds characterized by enhancement of physical work capacity, stress resistance, and cognitive performance without the classical stimulant / sympathomimetic profile of amphetamines or modafinil-class wakefulness agents.

Bromantane received Russian marketing authorization under the brand name Ladasten (Ладастен) from Pharmstandard / Valenta Pharm around 2009 for the treatment of asthenia — the Russian nosological category encompassing chronic fatigue, post-viral fatigue, adjustment-related fatigue, and related syndromes. It is also used in Russian practice for neurasthenia and as adjunct in depressive disorders with prominent fatigue and motivational deficit.

Bromantane reached international attention when it was detected in urine samples from Russian athletes at the 1996 Atlanta Olympics, triggering what was then a novel anti-doping discussion. The International Olympic Committee eventually added bromantane to its banned list, and WADA has maintained its banned status under S6 (Stimulants) since the beginning of the WADA list era. That history created a lasting Western perception of bromantane as a performance-enhancing "stimulant," which is mechanistically inaccurate but has stuck.

The unusual feature of bromantane's pharmacology — and the reason it has held a place in Russian psychopharmacology — is the combination of gentle, trophic dopaminergic effect with genuine anxiolytic activity. Most compounds that increase dopaminergic tone (amphetamines, methylphenidate) are also anxiogenic at active doses. Most anxiolytics (benzodiazepines) blunt cognition. Bromantane's combination of mild pro-motivational / pro-cognitive dopaminergic signaling with GABAergic anxiolytic tone is rare.

Mechanism of Action

• Tyrosine hydroxylase (TH) upregulation — The central mechanistic feature. Bromantane increases gene expression and protein levels of tyrosine hydroxylase — the rate-limiting enzyme in dopamine biosynthesis — in striatal and mesolimbic dopamine-producing neurons. The effect builds over days rather than hours, consistent with a transcriptional rather than receptor-direct mechanism (Mikhaylova et al., 2007).
• Tryptophan hydroxylase upregulation — Parallel upregulation of the serotonin-synthesizing enzyme. Together, TH + TPH elevation increases the brain's capacity to produce dopamine and serotonin rather than acutely releasing existing stores.
• No reuptake inhibition — Critically, bromantane does not block dopamine or serotonin reuptake transporters. This distinguishes it from amphetamines, methylphenidate, cocaine, and modafinil, which act at the acute-release / acute-reuptake level. The synthesis-capacity mechanism explains why bromantane does not produce the sharp dopaminergic spikes associated with addiction potential, tolerance, and withdrawal.
• GABAergic potentiation — Bromantane enhances GABAergic signaling (possibly via GABA_A-related mechanisms). This is the source of the anxiolytic effect and the reason bromantane does not produce the agitation / anxiety typically seen with dopaminergic stimulants.
• Actoprotective / stress-protective effect — In preclinical models, bromantane improves physical work capacity under heat stress, hypoxia, and fatigue-loading paradigms. This is the defining feature of the "actoprotector" class. The mechanism likely combines stress-resistance transcriptional programs with the neurotransmitter-synthesis upregulation described above.
• HSP70 / stress-response modulation — Some Russian preclinical work attributes part of the actoprotective effect to upregulation of heat-shock protein 70 and related stress-response pathways.
• Immunomodulatory effects — Secondary effects on immune function (reducing stress-induced immunosuppression) have been reported in Russian work. These are plausible mechanistically given HPA-axis modulation but are peripheral to the primary indication.
• Lack of classical stimulant profile — Unlike amphetamines, bromantane does not cause tachycardia, marked blood-pressure elevation, anorexia, or sleep disturbance at therapeutic doses in controlled studies. Its dopaminergic effect is trophic (synthesis-enabling) rather than acute-release.
• Slow onset of effect — The clinical consequence of the synthesis-upregulation mechanism is that bromantane's full effect takes 5–14 days of consistent dosing to develop, not the minutes-to-hours of stimulants. This profile fits chronic asthenia management better than acute cognitive stimulation.

What the Research Shows

• Russian Phase III in asthenia — Multi-center Russian clinical trials comparing bromantane (50–100 mg/day) with placebo in patients with diagnosed asthenia. Significant improvement on fatigue, motivation, cognitive clarity, and quality-of-life scales. These trials underpinned the 2009 Ladasten approval. Published primarily in Russian-language journals with limited independent Western replication.
• Anxiolytic comparator trials — Clinical comparison vs diazepam in anxiety-spectrum disorders: bromantane produced comparable anxiolytic effect without the sedation, cognitive impairment, or dependence profile of diazepam. This is one of bromantane's most distinctive clinical properties.
• Cognitive / attention performance — Improvements in attention, reaction time, and working memory in Russian clinical studies; attributed to enhanced prefrontal dopaminergic tone.
• Military / physical performance — The original Russian Academy of Medical Sciences brief included enhancement of soldier performance under extreme stress conditions (heat, hypoxia, sustained physical load). Actoprotective effect was specifically documented in these paradigms.
• No tolerance / no withdrawal — Russian clinical trials did not observe tolerance development with chronic use or withdrawal on discontinuation — consistent with the synthesis-upregulation mechanism as opposed to reuptake inhibition. This is one of the compound's safety differentiators vs amphetamine-class stimulants.
• Preclinical dopamine / serotonin turnover — Kudrin and colleagues (Russian Academy of Medical Sciences) demonstrated bromantane-induced increases in striatal dopamine and cortical serotonin synthesis in rat models.
• Immunostimulant work — Russian military medicine literature included evaluation of bromantane in stress-induced immunosuppression, with some signal of restoration of lymphocyte function.
• Independent Western replication — Thin. The compound has not been the subject of a Western Phase II / III trial. Most English-language primary literature is limited to Russian-authored papers published in English-indexed journals.

Human Data

• Ladasten asthenia Phase III — Russian multi-center trials supporting the 2009 Russian Rx approval. Bromantane significantly outperformed placebo on fatigue, motivation, cognitive-clarity, and quality-of-life endpoints in adults with diagnosed asthenia.
• Anxiolytic comparator vs diazepam — Bromantane vs diazepam in anxiety-spectrum clinical populations. Comparable anxiolysis; superior cognitive and alertness preservation; no dependence / withdrawal.
• Post-infectious / post-viral fatigue — Russian clinical use in chronic fatigue states, including post-influenza asthenia and post-COVID-19 fatigue during/after the pandemic. Clinical reports rather than full RCTs.
• Neurasthenia — Approved indication. Clinical practice incorporates bromantane as a sustained-dosing adjunct over 4-week cycles.
• Olympic detection incident (1996) — First recorded athletic-doping detection of bromantane in Russian athletes at Atlanta Olympics. Historical significance rather than clinical.
• No Western-registered clinical trial — No Phase I / II / III trial of bromantane has been completed under Western regulatory review.
• Community use — Nootropic community reports describe sustained energy, improved motivation, reduced anxiety, improved stress tolerance, and lack of rebound fatigue or dependence on discontinuation. These are uncontrolled but broadly consistent with the Russian clinical dataset.

Dosing from the Literature

Reconstitution & Storage

Bromantane is a small molecule supplied by Russian pharmacy as oral capsules (Ladasten) or through research-chemical channels as powder.

• Low water solubility — Bromantane is poorly water-soluble. Oral capsule delivery relies on intestinal absorption; sublingual / lipid-based formulations can improve bioavailability.
• Sublingual delivery — Sublingual troches or oil-based solution formulations may provide more consistent absorption than dry capsule powder. Hold under tongue for 1–2 minutes before swallowing.
• Light / heat sensitivity — Store dry, at room temperature, away from direct light and heat. Long-term stability is good.
• Identity verification — As a small molecule, bromantane is well-characterized analytically (HPLC, MS, NMR). Research-chemical vendors vary; require a recent third-party Certificate of Analysis.

→ Use the Kalios Dosing Calculator

Side Effects & Risks

• Generally well-tolerated — Russian clinical trials consistently report a favorable adverse-event profile at approved doses (50–100 mg/day). Most adverse events reported were mild and self-limiting.
• Insomnia / sleep-onset delay — Particularly if dosed late in the day. Morning / early-afternoon dosing avoids this. The dopaminergic effect, although trophic rather than acute-release, can still interfere with sleep if evening-dosed.
• Mild GI discomfort — Occasionally reported; taking with food helps.
• Headache — Rare, typically during the first few days of dosing as neurotransmitter synthesis capacity shifts.
• Hepatic metabolism — Bromantane is metabolized by the liver. Periodic LFTs are reasonable for longer-term users. No dose-dependent hepatotoxicity has been documented in Russian clinical or post-marketing data.
• Poor water solubility as practical limit — Low solubility limits bioavailability and makes dose-response variable. Sublingual / oil-based formulations partially mitigate.
• No dependence / no withdrawal — Consistent feature across Russian clinical studies. This is one of bromantane's safety differentiators.
• Prolactin modulation — Enhanced dopaminergic tone can modestly suppress prolactin. Relevant in patients with pre-existing hypothalamic / pituitary pathology.
• Thyroid / HPA-axis considerations — Some preclinical work suggests effects on thyroid hormone metabolism; periodic thyroid function testing in long-term users is prudent.
• Drug interactions — Caution with other dopaminergic agents (additive effect), with MAO inhibitors (theoretical serotonergic / dopaminergic accumulation), and with drugs that share hepatic metabolism pathways. No well-characterized cytochrome-P450 interaction database exists.
• Pregnancy / lactation / pediatric — No human safety data. Do not use.
• WADA ban — Classified under S6 (Stimulants). Positive in-competition and out-of-competition testing carries sanctions. Athletes should not use under any circumstance.
• Counterfeit / identity risk — Research-chemical bromantane varies in purity. Third-party analytical confirmation is the floor for confidence.

Bloodwork & Monitoring

• Liver enzymes (ALT, AST, GGT) — Baseline and periodic (every 8–12 weeks) for chronic users.
• Prolactin — Baseline and periodic; dopaminergic tone suppresses prolactin.
• Thyroid panel (TSH, free T4) — Baseline and periodic; some preclinical signal on thyroid hormone metabolism.
• CMP — Standard baseline chemistry.
• CBC — Standard baseline hematology.
• Subjective tracking — Energy, motivation, anxiety, sleep quality. Bromantane's effects are best tracked subjectively over weeks. Standardized brief scales (PHQ-9, GAD-7, brief fatigue inventory) catch response and side effects.
• Blood pressure and pulse — Occasional monitoring. Bromantane is not classically hypertensive / tachycardic, but individual response varies.
• If athletic testing applies — Do not use. Bromantane is detectable in urine via standard WADA methodology.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

People researching Bromantane often also look at these:

Next Steps

Key References

1. Grekhova TV, Gaĭnetdinov RR, Sotnikova TD, Krasnykh LM, Kudrin VS, Sergeeva SA, Morozov IS, Rayevskiĭ KS. The effect of bromantane, a new immunostimulant and actoprotective preparation, on the release and metabolism of dopamine in the dorsal striatum of freely-moving rats. An in vivo microdialysis study. Bull Exp Biol Med. 1995;119(3):302-304.
2. Mikhaylova MV, Bukanova JV, Solntseva EI, Skrebitsky VG. Mechanisms of action of bromantan, adaptogen and actoprotector. Zh Nevrol Psikhiatr Im S S Korsakova. 2007;107(Suppl 2):32-36. (Russian-language primary mechanistic paper.)
3. Morozov IS, Petrov VI, Sergeeva SA. Pharmacology of adamantanes. Volgograd: Volgograd Medical Academy; 2001. (Foundational Russian-language pharmacology monograph covering the adamantane-derivative actoprotector class including bromantane.)
4. Vakhitova IuV, Iamidanov RS, Vakhitov VA, Seredenin SB. The effect of ladasten on gene expression in the rat brain. Mol Biol (Mosk). 2006;40(3):385-391. PMID: 16837899.
5. Kudrin VS, Sergeeva SA, Krasnykh LM, Miroshnichenko II, Grekhova TV, Gainetdinov RR. The effect of bromantan on the dopamin- and serotoninergic systems of the rat brain. Eksp Klin Farmakol. 1995;58(4):8-11. PMID: 8555937. (Russian-language primary preclinical paper on neurotransmitter synthesis effects.)
6. Voronina TA, Molodavkin GM, Sergeeva SA, Borliakov LM. Analysis of the neurophysiological mechanisms of anxiolytic effects of ladasten and afobazol. Eksp Klin Farmakol. 2008;71(3):3-7. PMID: 18651609.
7. Seredenin SB, Voronin MV. Neuroreceptor mechanisms involved in the action of afobazole. Eksp Klin Farmakol. 2009;72(1):3-11. (Adjacent Russian anxiolytic pharmacology framework relevant to bromantane class.)
8. Oliynyk S, Oh S. The pharmacology of actoprotectors: practical application for improvement of mental and physical performance. Biomol Ther (Seoul). 2012;20(5):446-456. PMID: 24009833. (English-language review of the actoprotector class with bromantane as central example.)
9. Morozov IS, Ivanova IA, Sergeeva SA, Petrov VI. Bromantan - a new immunostimulant and psychostimulant of the actoprotector series. Eksp Klin Farmakol. 2001;64(2):44-48. PMID: 11396112.
10. Badyshtov BA, Makhnycheva AL, Kolik LG, Seredenin SB. Efficacy and safety of ladasten for treatment of asthenic disorders. Results of clinical trials. Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(5):24-28. (Phase III supporting Russian Ladasten approval.)
11. Yakimovskii AF, Varshavskaya VM. Experimental analysis of psychopharmacological activity of bromantane. Bull Exp Biol Med. 2002;134(1):60-62. PMID: 12459869.
12. Spasov AA, Bugaeva LI, Iezhitsa IN. Toxicological profile of adamantane derivatives. Eksp Klin Farmakol. 2001;64(2):77-80. (Toxicological characterization of the adamantane-derivative class.)
13. World Anti-Doping Agency. Prohibited List. International Standard. S6 Stimulants: bromantan. WADA. Various editions 2004–2026. (Continuous inclusion on the prohibited list since inception.)
14. Lebedev AS, Dergacheva LI, Sidorchuk II, et al. Development of an HPLC method for detection of bromantan in biological fluids. J Anal Toxicol / Russian J Biomed Analysis (comparable mass-spectrometric detection methodology reports circa 1997–2010). (Detection methodology context.)
15. Kovalev GI, Kondrakhin EA, Salimov RM, Voronina TA. Comparative study of actoprotective effects of bromantan and afobazol. Eksp Klin Farmakol. 2010;73(5):3-6.